Cargando…
Short-Term Peg-IFN α-2b Re-Treatment Induced a High Functional Cure Rate in Patients with HBsAg Recurrence after Stopping Peg-IFN α-Based Regimens
Little is known about the treatment of patients with hepatitis B surface antigen (HBsAg) recurrence after being clinically cured by peginterferon alpha(peg-IFN-α)-based regimens. This study aimed to investigate the efficacy and safety of peg-IFNα-2b in re-treating patients with HBsAg recurrence afte...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821570/ https://www.ncbi.nlm.nih.gov/pubmed/36615161 http://dx.doi.org/10.3390/jcm12010361 |
_version_ | 1784865729122664448 |
---|---|
author | Wu, Fengping Wang, Yikai Cui, Dandan Tian, Yan Lu, Rui Liu, Chenrui Li, Mei Li, Yaping Gao, Ning Jiang, Zicheng Li, Xuemei Zhai, Song Zhang, Xin Jia, Xiaoli Dang, Shuangsuo |
author_facet | Wu, Fengping Wang, Yikai Cui, Dandan Tian, Yan Lu, Rui Liu, Chenrui Li, Mei Li, Yaping Gao, Ning Jiang, Zicheng Li, Xuemei Zhai, Song Zhang, Xin Jia, Xiaoli Dang, Shuangsuo |
author_sort | Wu, Fengping |
collection | PubMed |
description | Little is known about the treatment of patients with hepatitis B surface antigen (HBsAg) recurrence after being clinically cured by peginterferon alpha(peg-IFN-α)-based regimens. This study aimed to investigate the efficacy and safety of peg-IFNα-2b in re-treating patients with HBsAg recurrence after stopping peg-IFN α-based regimens. In this two-center, prospective observational study, 33 patients with HBsAg recurrence after stopping peg-IFN α-based regimens were enrolled and re-treated with an individualized course of peg-IFN α-2b. The hepatitis B virus (HBV) vaccine could be injected immediately after HBsAg clearance, according to patients’ willingness. All patients were monitored and followed-up for 48 weeks after peg-IFN α-2b re-treatment stop. The primary endpoint was HBsAg clearance at the end of follow-up. At baseline, all patients had HBsAg levels of <10 IU/mL and undetectable HBV DNA, with the median HBsAg level of 1.66 (0.56–2.87) IU/mL. After a median of 24 (24–30) weeks of peg-IFN α-2b re-treatment, 87.9% (29/33) of the patients achieved HBsAg clearance again and 66.7% (22/33) of the patients achieved HBsAg seroconversion. At the end of follow-up, the HBsAg clearance and HBsAg seroconversion rates decreased to 78.8% (26/33) and 51.5% (17/33), respectively. Furthermore, 88.9% (16/18) of the patients with HBsAg clearance benefited from receiving the HBV vaccine therapy. Generally, both peg-IFN α-2b and HBV vaccine therapy were well tolerated. A high functional cure rate can be achieved by a short-course of peg-IFN α-2b re-treatment in patients with HBsAg recurrence after stopping peg-IFN α-based regimens. Furthermore, injecting HBV vaccine is beneficial after HBsAg clearance. |
format | Online Article Text |
id | pubmed-9821570 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98215702023-01-07 Short-Term Peg-IFN α-2b Re-Treatment Induced a High Functional Cure Rate in Patients with HBsAg Recurrence after Stopping Peg-IFN α-Based Regimens Wu, Fengping Wang, Yikai Cui, Dandan Tian, Yan Lu, Rui Liu, Chenrui Li, Mei Li, Yaping Gao, Ning Jiang, Zicheng Li, Xuemei Zhai, Song Zhang, Xin Jia, Xiaoli Dang, Shuangsuo J Clin Med Article Little is known about the treatment of patients with hepatitis B surface antigen (HBsAg) recurrence after being clinically cured by peginterferon alpha(peg-IFN-α)-based regimens. This study aimed to investigate the efficacy and safety of peg-IFNα-2b in re-treating patients with HBsAg recurrence after stopping peg-IFN α-based regimens. In this two-center, prospective observational study, 33 patients with HBsAg recurrence after stopping peg-IFN α-based regimens were enrolled and re-treated with an individualized course of peg-IFN α-2b. The hepatitis B virus (HBV) vaccine could be injected immediately after HBsAg clearance, according to patients’ willingness. All patients were monitored and followed-up for 48 weeks after peg-IFN α-2b re-treatment stop. The primary endpoint was HBsAg clearance at the end of follow-up. At baseline, all patients had HBsAg levels of <10 IU/mL and undetectable HBV DNA, with the median HBsAg level of 1.66 (0.56–2.87) IU/mL. After a median of 24 (24–30) weeks of peg-IFN α-2b re-treatment, 87.9% (29/33) of the patients achieved HBsAg clearance again and 66.7% (22/33) of the patients achieved HBsAg seroconversion. At the end of follow-up, the HBsAg clearance and HBsAg seroconversion rates decreased to 78.8% (26/33) and 51.5% (17/33), respectively. Furthermore, 88.9% (16/18) of the patients with HBsAg clearance benefited from receiving the HBV vaccine therapy. Generally, both peg-IFN α-2b and HBV vaccine therapy were well tolerated. A high functional cure rate can be achieved by a short-course of peg-IFN α-2b re-treatment in patients with HBsAg recurrence after stopping peg-IFN α-based regimens. Furthermore, injecting HBV vaccine is beneficial after HBsAg clearance. MDPI 2023-01-02 /pmc/articles/PMC9821570/ /pubmed/36615161 http://dx.doi.org/10.3390/jcm12010361 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Wu, Fengping Wang, Yikai Cui, Dandan Tian, Yan Lu, Rui Liu, Chenrui Li, Mei Li, Yaping Gao, Ning Jiang, Zicheng Li, Xuemei Zhai, Song Zhang, Xin Jia, Xiaoli Dang, Shuangsuo Short-Term Peg-IFN α-2b Re-Treatment Induced a High Functional Cure Rate in Patients with HBsAg Recurrence after Stopping Peg-IFN α-Based Regimens |
title | Short-Term Peg-IFN α-2b Re-Treatment Induced a High Functional Cure Rate in Patients with HBsAg Recurrence after Stopping Peg-IFN α-Based Regimens |
title_full | Short-Term Peg-IFN α-2b Re-Treatment Induced a High Functional Cure Rate in Patients with HBsAg Recurrence after Stopping Peg-IFN α-Based Regimens |
title_fullStr | Short-Term Peg-IFN α-2b Re-Treatment Induced a High Functional Cure Rate in Patients with HBsAg Recurrence after Stopping Peg-IFN α-Based Regimens |
title_full_unstemmed | Short-Term Peg-IFN α-2b Re-Treatment Induced a High Functional Cure Rate in Patients with HBsAg Recurrence after Stopping Peg-IFN α-Based Regimens |
title_short | Short-Term Peg-IFN α-2b Re-Treatment Induced a High Functional Cure Rate in Patients with HBsAg Recurrence after Stopping Peg-IFN α-Based Regimens |
title_sort | short-term peg-ifn α-2b re-treatment induced a high functional cure rate in patients with hbsag recurrence after stopping peg-ifn α-based regimens |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821570/ https://www.ncbi.nlm.nih.gov/pubmed/36615161 http://dx.doi.org/10.3390/jcm12010361 |
work_keys_str_mv | AT wufengping shorttermpegifna2bretreatmentinducedahighfunctionalcurerateinpatientswithhbsagrecurrenceafterstoppingpegifnabasedregimens AT wangyikai shorttermpegifna2bretreatmentinducedahighfunctionalcurerateinpatientswithhbsagrecurrenceafterstoppingpegifnabasedregimens AT cuidandan shorttermpegifna2bretreatmentinducedahighfunctionalcurerateinpatientswithhbsagrecurrenceafterstoppingpegifnabasedregimens AT tianyan shorttermpegifna2bretreatmentinducedahighfunctionalcurerateinpatientswithhbsagrecurrenceafterstoppingpegifnabasedregimens AT lurui shorttermpegifna2bretreatmentinducedahighfunctionalcurerateinpatientswithhbsagrecurrenceafterstoppingpegifnabasedregimens AT liuchenrui shorttermpegifna2bretreatmentinducedahighfunctionalcurerateinpatientswithhbsagrecurrenceafterstoppingpegifnabasedregimens AT limei shorttermpegifna2bretreatmentinducedahighfunctionalcurerateinpatientswithhbsagrecurrenceafterstoppingpegifnabasedregimens AT liyaping shorttermpegifna2bretreatmentinducedahighfunctionalcurerateinpatientswithhbsagrecurrenceafterstoppingpegifnabasedregimens AT gaoning shorttermpegifna2bretreatmentinducedahighfunctionalcurerateinpatientswithhbsagrecurrenceafterstoppingpegifnabasedregimens AT jiangzicheng shorttermpegifna2bretreatmentinducedahighfunctionalcurerateinpatientswithhbsagrecurrenceafterstoppingpegifnabasedregimens AT lixuemei shorttermpegifna2bretreatmentinducedahighfunctionalcurerateinpatientswithhbsagrecurrenceafterstoppingpegifnabasedregimens AT zhaisong shorttermpegifna2bretreatmentinducedahighfunctionalcurerateinpatientswithhbsagrecurrenceafterstoppingpegifnabasedregimens AT zhangxin shorttermpegifna2bretreatmentinducedahighfunctionalcurerateinpatientswithhbsagrecurrenceafterstoppingpegifnabasedregimens AT jiaxiaoli shorttermpegifna2bretreatmentinducedahighfunctionalcurerateinpatientswithhbsagrecurrenceafterstoppingpegifnabasedregimens AT dangshuangsuo shorttermpegifna2bretreatmentinducedahighfunctionalcurerateinpatientswithhbsagrecurrenceafterstoppingpegifnabasedregimens |